A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs AMG 232 (Primary) ; Dabrafenib; Trametinib
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Amgen
- 14 Dec 2018 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Planned End Date changed from 17 Aug 2021 to 15 Oct 2019.
- 14 Feb 2018 Planned primary completion date changed from 15 Apr 2018 to 15 Oct 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History